Physician profile
Gary D Palmer
NPI 1134124563
$7,642.51
in general payments reported to CMS, 2019-2025
26 companies · $888 in 2025
The $888 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,178 · 2020: $598 · 2021: $735 · 2022: $999 · 2023: $1,498 · 2024: $1,747 · 2025: $888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,950 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,950.06 |
| Education | $182.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,530.49 | 2019-2025 | |
| Lilly USA, LLC | $1,097.85 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $635.41 | 2019-2025 | |
| Janssen Biotech, INC. | $573.21 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Ucb, INC. | $547.60 | 2019-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $403.94 | 2023-2025 | Zoryve |
| Pfizer INC. | $345.60 | 2019-2025 | |
| Dermavant Sciences, INC. | $255.84 | 2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $233.69 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $212.37 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $152.05 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $128.92 | 2022-2024 | Sotyktu |
| Merz North America, INC. | $127.71 | 2019 | |
| Allergan, INC. | $57.78 | 2019-2022 | |
| Galderma Laboratories, L.P. | $52.59 | 2022-2025 | Dysport |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $44.78 | 2024 | Otezla |
| Almirall LLC | $39.26 | 2019-2025 | Seysara |
| Regeneron Healthcare Solutions, INC. | $39.04 | 2024 | Dupixent |
| Biofrontera INC. | $28.05 | 2022 | |
| Sanofi-Aventis U.S. LLC | $21.94 | 2021 | |
| Aclaris Therapeutics, INC. | $21.77 | 2019 | |
| Leo Pharma INC. | $21.28 | 2020 | |
| Organon LLC | $20.81 | 2025 | Vtama |
| Incyte Corporation | $18.82 | 2023 | Opzelura |
| Janssen Scientific Affairs, LLC | $16.63 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $15.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Palmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.